Multaq Tablet, Film Coated
Product Images NDC 0024-4142

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Multaq (NDC 0024-4142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Multaq 01)

Chemical structure of Dronedarone, the active ingredient in Multaq 400 mg film-coated tablets. The structure shows the molecular arrangement, including aromatic rings and functional groups characteristic of this compound.*

FDA Label Image

Figure 1 (Multaq 02)

A forest plot chart depicting the drug interaction effects of various drugs with Dronedarone. The chart shows mean ratios and 90% confidence intervals for Cmax and AUC values, comparing the change relative to dronedarone alone. Interacting drugs are categorized into antibiotics, grapefruit juice, calcium channel blockers, statins, AIIRA, and other, with recommendations ranging from contraindicated to no dose adjustment.*

FDA Label Image

Figure 2 (Multaq 03)

A forest plot chart showing the mean ratio and 90% confidence interval of pharmacokinetic changes (Cmax and AUC) for various drugs interacting with a treatment. The x-axis represents change relative to the interacting drug alone, with pharmacokinetic measures indicated by red circles (Cmax) and green triangles (AUC). Drugs are categorized and listed on the left with dosing information, and dosing recommendations are provided on the right.*

FDA Label Image

Figure 3 (Multaq 04)

A line graph showing cumulative incidence over 30 months comparing Placebo and Dronedarone groups. The x-axis represents time in months, and the y-axis represents cumulative incidence from 0.0 to 0.5. Two lines indicate the incidence trends for Placebo (solid line) and Dronedarone (dashed line), with Placebo exhibiting a higher cumulative incidence throughout. A table below the graph provides the number of subjects at risk at various time points for each group.*

FDA Label Image

Figure 2 (Multaq 05)

A forest plot chart depicting relative risks (RR) with 95% confidence intervals for various patient characteristics comparing Dronedarone to placebo. The chart includes subgroups by age, gender, presence of atrial fibrillation/flutter, structural heart disease, NYHA class, left ventricular ejection fraction, and use of beta-blockers, ACE inhibitors or ARBs, digitalis, and calcium antagonists. Each characteristic has plotting points with confidence intervals shown horizontally, indicating treatment effect across subgroups.*

FDA Label Image

Principal Display Panel (60 Tablet Bottle)

Multaq (dronedarone) 400 mg film-coated tablets label by Sanofi-Aventis U.S. LLC. The label indicates 60 tablets per container, with directions to dispense with a Medication Guide. Packaging includes NDC 0024-4142-60, storage instructions, and a section for serial number, lot, and expiration date. Origin noted as France.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.